Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown significant market activity, with a recent increase of 3.38% and a trading volume of 170 million yuan, indicating strong investor interest in the innovative drug sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) reached a new high in both scale and shares since its inception as of October 31 [1] - The ETF has experienced net inflows for 4 out of the last 5 trading days, totaling 18.9 million yuan [1] - The index it tracks, the National Certificate Hong Kong Stock Connect Innovative Drug Index, rose by 3.67%, with notable increases in component stocks such as Senhwa Biosciences (up 10.11%) and Kanglongda (up 8.80%) [1] Group 2: Policy and Industry Insights - The ongoing negotiations for the National Medical Insurance drug list are complemented by a new commercial health insurance innovative drug directory, aimed at providing new payment channels for high-value innovative drugs [1] - The CAR-T cell drug, Rukiyou Lunsai injection from WuXi AppTec, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, with a listed price of 1.29 million yuan per injection [1] - Open Source Securities notes that the current innovative drugs included in both medical insurance and commercial insurance are in the early stages of volume growth, with potential for rapid revenue increases as policies continue to support innovative drugs [2] Group 3: Institutional Investment Trends - According to Guotou Securities, the proportion of all funds heavily invested in Biotech innovative drug companies has increased to 27.53%, reflecting a 2.61 percentage point rise, indicating growing institutional interest in the innovative drug sector [2] - The increasing allocation of funds to the innovative drug sector suggests a strong market recognition of its long-term development potential [2]

Group 1: Market Overview - The Hang Seng Index (HSI) has shown a bearish sentiment, with some investors predicting a drop to 25,800 points, while others are looking at call options with a strike price of 28,743 points [1][2] - The HSI closed at approximately 25,906 points, indicating a significant decline, and the support level is around 25,500 points, with a potential drop to 25,000 points if this level is breached [1][2] Group 2: AIA Group (01299.HK) - AIA Group's stock price increased today, reaching a high of 76.8 HKD, with a closing price of around 75.45 HKD, and investors are optimistic about it surpassing 77 HKD, potentially reaching 90 HKD in the long term [8] - The resistance level for AIA Group is at 78.7 HKD, and if it breaks this level, it could rise to 80.3 HKD [8] Group 3: China Mobile (00941.HK) - China Mobile's stock price experienced a decline, closing at 85.25 HKD, with a support level at 82.1 HKD, and a potential drop to 78.8 HKD if this level is broken [11][12] - Investors are considering call options with a strike price of 99.4 HKD, expiring in December, but there are concerns about time decay due to the short duration [12] Group 4: China Biologic Products (01177.HK) - The stock price of China Biologic Products has been relatively stable, closing at 7.07 HKD after a low of 6.74 HKD, with a support level at 6.73 HKD [18] - There are currently more buy signals (9) than sell signals (6), indicating a potential buying opportunity [18] Group 5: Baidu Group-SW (09888.HK) - Baidu's stock price closed at 117.6 HKD, with a support level at 113.4 HKD, and a potential drop to 108.8 HKD if this level is breached [20] - Investors are considering put options due to the significant decline in trading volume [20] Group 6: Tencent Holdings (00700.HK) - Tencent's stock price closed at 629 HKD, with a support level at 613 HKD, and a potential drop to 591 HKD if it falls below this level [27] - Investors are advised to choose options with strike prices close to the current price to avoid issues with price tracking [27][28]

Core Insights - The Hong Kong pharmaceutical market is experiencing a significant rebound, driven by the recent national negotiations regarding innovative drug pricing, with the Hong Kong Stock Connect Innovative Drug ETF (159570) surging over 2% and achieving a trading volume exceeding 3.2 billion CNY [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has seen a net inflow of nearly 700 million CNY during the trading session, indicating strong investor interest [1]. - As of October 31, the ETF's latest scale has surpassed 20.3 billion CNY, leading in both scale and liquidity among its peers [1]. - The top ten constituent stocks of the ETF account for 72.47% of its weight, showcasing a concentrated investment in innovative pharmaceuticals [7]. Group 2: Company Developments - Innovative drug companies are gaining attention due to the ongoing negotiations for the 2025 National Medical Insurance Directory, which includes a new commercial health insurance innovative drug directory [3]. - Notably, CAR-T cell therapy companies are in focus, with five high-cost CAR-T therapies passing the initial review for the commercial insurance directory, potentially increasing patient access [3]. - In Q3 2025, Innovent Biologics reported a total product revenue exceeding 3.3 billion CNY, reflecting a robust year-on-year growth of approximately 40%, driven by strong performance in oncology and other therapeutic areas [6][7]. Group 3: Clinical Trials and Global Expansion - Innovent Biologics and Pfizer have initiated two global Phase III clinical trials for their PD-1/VEGF dual antibody, SSGJ-707, targeting advanced non-small cell lung cancer and metastatic colorectal cancer [6]. - The trials are expected to enroll 1,500 and 800 patients respectively, with completion dates projected for early 2029 and early 2030, indicating a strong commitment to global market entry [6]. Group 4: Industry Outlook - Analysts suggest that the ongoing policy support for innovative drugs will likely lead to rapid revenue growth for those included in the medical insurance directory, benefiting both patients and pharmaceutical companies [4]. - The innovative drug sector is expected to continue its upward trajectory, with leading companies making significant progress both domestically and internationally [4][6].

Summary of the Conference Call on Chinese Innovative Pharmaceuticals Industry Overview - The Chinese innovative pharmaceutical industry is transitioning from a follower to a leader, particularly in areas such as bispecific antibodies, multi-target therapies, antibody-drug conjugates (ADCs), and targeted therapies [1][4] - The industry benefits from population and domestic demand advantages, manufacturing and supply chain capabilities, and rapidly improving innovation capabilities, leading to increased global competitiveness and asset outflows [1][5] Key Insights from ESMO 2025 - At the 2025 European Society for Medical Oncology (ESMO) conference, Chinese scholars had 23 studies selected for breakthrough abstracts, with three entering the podium for oral presentations, marking a historical high [3] - Notable performances included: - Rongchang Biopharma's ADC data in urothelial carcinoma with a PFS of 13.1 months and HR of 0.36 [3][10] - Kanglin Jere's dual HER2 ADC JSK 003 showing a DCR exceeding 96% in colorectal cancer patients [3][11] - Lepu Biopharma's TFADC for pancreatic cancer achieving a PFS of 5.8 months and MOS of 13.2 months [3][11] - Other companies like Hengrui Medicine and Jinfang also showed promising results in the KRS field [3][12] Future Developments - In 2026, Kolun Biotechnology plans to release overseas data, while Bai Li Tianheng will continue to publish significant data in nasopharyngeal carcinoma and multiple phase III clinical results [9][13] - The industry is expected to see a shift from phase I and II clinical trials to phase III, indicating a positive development trend [10] Impact of Policy Reforms - Chinese pharmaceutical policy reforms have entered a deep-water zone, with high-quality growth becoming the norm. Anticipated catalysts for industry growth include ongoing business development activities and overseas data releases from late 2025 to 2026 [6] Competitive Landscape - Chinese pharmaceutical companies are gaining ground internationally, with significant advancements in innovative drug development. Companies like Hengrui, Jinfang, and others are noted for their competitive performance [5][12][14] - The U.S. faces challenges such as patent cliffs and potential business declines, necessitating acquisitions to compensate for these issues [5] Noteworthy Research Findings - Key targets discussed at ESMO included PD-1, PD-L1, HER2 family, CDK4/6, and VEGFR [7] - Data from various companies showed promising outcomes, such as: - CMAX overall OR of 68.8% and DCR of 93.8% from Aosaikang [12] - CDK246 from China Biopharma achieving an OR of 59.3% in first-line breast cancer treatment [12] Conclusion - The Chinese innovative pharmaceutical sector is poised for significant growth and international recognition, with numerous data releases expected in the coming months and throughout 2026, reflecting a shift from following to leading in the global market [13]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物製藥有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.025 HKD | | 750,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 30,000,000,000 | | HKD | | 0.025 HKD | | 750,000,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - The innovative drug sector experienced a significant surge on October 31, with notable performances in both A-shares and Hong Kong stocks, driven by the initiation of the 2025 national medical insurance negotiations and the introduction of a "commercial insurance innovative drug catalog" mechanism [1][3]. Group 1: Market Performance - The A-share innovative drug ETF (562050) rose by 2.46%, while the Hong Kong innovative drug ETF (520880) surged by 5.25%, indicating high elasticity in the sector [1]. - Major stocks such as Sanofi and InnoCare Pharmaceuticals saw gains of 11% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [4][5]. Group 2: Policy and Market Drivers - The introduction of the "commercial insurance innovative drug catalog" is expected to alleviate the payment pressure for high-value innovative drugs [1][3]. - The recent meeting between U.S. and Chinese leaders has reduced potential risk factors that previously suppressed the sector's performance, leading to a possible influx of capital back into the market [3]. - The ongoing earnings season, with strong performances from companies like Innovent Biologics and Hengrui Medicine, is boosting confidence in the sector [3]. Group 3: Technical Analysis - The Hong Kong innovative drug ETF (520880) has shown a significant bullish trend, breaking through key moving averages and indicating a potential reversal in market sentiment [1]. - The MACD indicator shows a notable reduction in bearish momentum, suggesting a shift towards bullish conditions [1]. Group 4: Fund Characteristics - The Hong Kong innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively includes innovative drug development companies [3][4]. - The top ten holdings account for 71.63% of the index, highlighting the dominance of leading companies in the sector [4].

Core Viewpoint - The article discusses the strategic opportunities and trends in the Chinese pharmaceutical and healthcare industry, emphasizing innovation and global expansion as key drivers for growth [3][4]. Group 1: Industry Trends - The current state and trends of the Chinese pharmaceutical and healthcare industry will be analyzed from a market perspective [3]. - The transformation of China's biopharmaceutical sector from catching up to leading globally is highlighted, focusing on innovative breakthroughs [4]. Group 2: Key Innovations - The success factors in the medical aesthetics industry will be decoded, showcasing the industry's growth potential [4]. - Innovations in the metabolic field, particularly regarding GLP-1 and the fourth-generation insulin, are being driven by dual engines at Ganli Pharmaceutical [4]. - The article mentions the emergence of a 2.0 era in targeted anti-tumor drugs and immunotherapy, indicating advancements in cancer treatment [4]. Group 3: Strategic Insights - The annual strategy report for the pharmaceutical industry will be presented, providing insights into future directions and investment opportunities [4]. - The establishment of a global new drug origin by Baiao Saitu is discussed, emphasizing the company's role in the international pharmaceutical landscape [4].

Investment Rating - The report assigns a "Leading" investment rating to the pharmaceutical industry as of October 31, 2025 [1] Core Insights - The eleventh batch of centralized procurement has seen significant price reductions, but the overall impact on the companies may be limited. The fourth quarter is expected to bring catalysts that could improve investor sentiment [4] - The report highlights that the pharmaceutical sector has experienced a notable price correction, but the fundamentals remain strong, with an anticipated stabilization in investment sentiment due to upcoming catalysts such as academic conferences and favorable policies [4] Summary by Sections Industry Performance - The Hang Seng Index rose by 2.2% during the week of October 22-29, 2025, while the Hang Seng Healthcare Index fell by 0.9%, ranking 12th among 12 industry indices [4][10] - Sub-industry performance varied, with CXO up by 4.6% and biopharmaceuticals down by 2.3% [4][10] Company Valuation Overview - A detailed valuation table lists various companies with their respective ratings, target prices, and earnings projections for FY25E and FY26E, indicating a generally bullish outlook with multiple "Buy" ratings [3] Institutional Holdings - As of October 28, 2025, the proportion of domestic institutional holdings in the pharmaceutical sector decreased slightly to 21.9%, while foreign holdings remained stable [36][39] - Domestic investors have shown a preference for increasing positions in medical device companies and "AI + healthcare" concepts, while foreign investors have focused on long-term potential in innovative drug companies [39][41] Procurement Insights - The eleventh batch of centralized procurement included 55 drug products, with a selection rate of 57%. The report notes that the impact on the overall revenue of selected companies is expected to be minimal [8][9] - The report identifies specific companies and the number of products selected in the procurement process, indicating a limited revenue contribution from these selections [8][9]

Industry Investment Rating - The report rates the pharmaceutical industry as "Leading" as of October 31, 2025 [1] Core Insights - The report highlights that the significant price reductions from the 11th batch of centralized procurement may have limited impact on the overall performance of the sector. However, catalysts in Q4 are expected to improve investor sentiment [4] - The report indicates that the pharmaceutical sector has experienced a notable price correction, but the fundamentals remain strong, with an anticipated stabilization in investment sentiment due to upcoming catalysts such as academic conferences and favorable policies [4] Summary by Relevant Sections Market Performance - The Hang Seng Index rose by 2.2% during the week of October 22-29, 2025, while the Hang Seng Healthcare Index fell by 0.9%, ranking 12th among 12 industry indices [4][10] - Sub-sectors showed varied performance, with CXO up by 4.6% and biopharmaceuticals down by 2.3% [4][10] Institutional Holdings - As of October 28, 2025, the proportion of domestic institutional holdings in the pharmaceutical sector decreased slightly to 21.9%, while foreign holdings remained stable [36][39] - Domestic investors have increased their positions in medical device companies and "AI + healthcare" concepts, while foreign investors have focused on long-term potential innovative drug companies [39] Procurement Insights - The 11th batch of centralized procurement included 55 drug products, with a selection rate of 57%. The report notes that the impact on the overall revenue of selected companies is expected to be limited [8][9] - Companies such as Kelun Pharmaceutical and China National Pharmaceutical have multiple products selected, but the overall contribution to revenue is anticipated to be small [8][9] Valuation Overview - The report provides a valuation summary for various companies, with target prices and earnings per share estimates for FY25E and FY26E, indicating a generally positive outlook for selected companies in the innovative drug sector [3] Investment Recommendations - The report recommends focusing on innovative drugs and CXO companies, highlighting specific firms such as Sanofi and WuXi AppTec as having strong short-term catalysts and undervalued growth potential [4]

Core Insights - The innovative drug sector has seen a significant rebound, with stocks like InnoCare Pharma rising over 12% and 3SBio increasing over 11% [1] - Positive developments in US-China relations and ongoing progress in external licensing transactions are contributing to this growth, particularly with a major deal by Innovent Biologics exceeding 10 billion [1] - The introduction of a "commercial insurance innovative drug catalog" mechanism in the national medical insurance negotiations is expected to benefit innovative drugs and devices [1] Group 1 - The innovative drug sector is experiencing a strong recovery, with major stocks showing significant gains, including InnoCare Pharma up over 12% and 3SBio up over 11% [1] - The third quarter results for Innovent Biologics show total product revenue exceeding 3.3 billion, reflecting a robust year-on-year growth of approximately 40% [1] - The upcoming national medical insurance negotiations are set to introduce a new mechanism that could enhance the market for innovative drugs [1] Group 2 - The Hang Seng Medical ETF has increased by 3.35%, with significant inflows of over 1.1 billion since early September, despite a previous decline of over 14% [2] - The Sci-Tech Innovation Board Medical ETF has risen by 3.93%, covering a range of innovative drugs and devices, with leading stocks including WuXi AppTec and BeiGene [2]